
PRESS RELEASE

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2026:

- 65,000 shares
- €973,620.20

During the first half of 2026, total trading was:

- On the buy side: 1,598,594 shares for a total amount of €12,813,126.30
- On the sell side: 1,549,771 shares for a total amount of €12,677,508.21

During this same period, the number of trades were:

- On the buy side: 3,200
- On the sell side: 2,721

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

- 27,911 shares
- €769,849.43

END

ABOUT GENFIT

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage

PRESS RELEASE

spanning more than two decades. Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT's expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.¹ Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements regarding its research and development programs. The use of certain words, such as "believe", "potential", "expect", "target", "may", "will", "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success

¹ Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo®

PRESS RELEASE

of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACTS

GENFIT | Investors

Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 | jean-christophe.marcoux@genfit.com

GENFIT | Media

Bruno ARABIAN – Agence Maarc | Tel: 06 87 88 47 26 | bruno.arabian@maarc.fr

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

PRESS RELEASE

APPENDIX
H1 2026

Date	Buy side			Sell-side		
	Number of executions	Number of shares	Traded amounts in EUR	Number of executions	Number of shares	Traded amounts in EUR
TOTAL	3 200	1 598 594	12 813 126,30	2 721	1 549 771	12 677 508,21
02/01/2026	40	23001	121 230,22	37	20343	107 679,57
05/01/2026	47	23176	119 431,26	28	12011	62 387,18
06/01/2026	1	1	5,16	16	7001	36 885,19
07/01/2026	21	17001	91 071,98	6	5001	27 580,41
08/01/2026	21	12858	67 922,90	4	858	4 483,16
09/01/2026	19	11001	58 085,17	18	11001	58 185,17
12/01/2026	28	14411	75 680,66	12	8118	42 907,20
13/01/2026	20	9330	48 857,66	20	9330	49 159,12
14/01/2026	7	5276	27 949,77	21	16569	88 827,90
15/01/2026	13	9098	49 201,53	14	7760	42 426,64
16/01/2026	24	9154	48 508,60	8	3492	18 417,79
19/01/2026	21	13001	67 455,17	25	9464	49 632,06
20/01/2026	28	16464	85 027,50	22	11001	56 805,20
21/01/2026	14	8001	40 975,20	17	11001	57 360,20
22/01/2026	15	11001	59 055,24	25	16001	86 454,20
23/01/2026	15	16011	88 481,11	16	10511	58 200,67
26/01/2026	25	14055	77 320,91	3	555	3 094,13
27/01/2026	18	5893	32 583,87	20	12893	71 491,69
28/01/2026	19	9685	54 619,53	34	14749	83 721,08
29/01/2026	15	8657	48 872,31	10	24593	139 052,27
30/01/2026	12	10000	56 410,00	13	7866	44 521,56
02/02/2026	17	7001	38 870,60	23	15135	85 648,97
03/02/2026	14	5132	31 188,29	29	15132	92 903,37
04/02/2026	22	10252	63 414,77	17	9252	57 898,65
05/02/2026	33	15001	94 081,17	24	13219	83 049,56
06/02/2026	41	19810	121 962,84	13	7002	43 432,71
09/02/2026	17	12450	76 738,31	30	19040	118 363,68
10/02/2026	16	7001	45 474,02	33	15001	97 038,92
11/02/2026	16	10403	68 835,82	27	14403	95 687,91
12/02/2026	24	15001	105 536,84	22	13001	92 381,73

PRESS RELEASE

13/02/2026	26	24001	168 262,13	31	18001	127 784,06
16/02/2026	11	11001	81 340,95	28	16001	117 972,33
17/02/2026	20	8751	69 255,15	19	8751	68 320,11
18/02/2026	19	8501	67 105,53	11	3501	27 958,04
19/02/2026	38	11503	89 218,65	34	14253	114 044,24
20/02/2026	46	22930	179 214,92	2	180	1 422,13
23/02/2026	1	1	8,19	38	20001	168 318,22
24/02/2026	40	17551	158 835,50	44	22551	205 596,79
25/02/2026	21	10001	89 761,68	18	5001	45 839,22
26/02/2026	49	22001	195 236,65	5	2001	18 409,06
27/02/2026	28	13001	119 358,93	41	13501	125 618,84
02/03/2026	52	20251	169 647,49	16	14751	128 083,52
03/03/2026	54	19001	162 346,25	19	9001	77 041,18
04/03/2026	23	7001	59 184,28	35	19501	168 798,12
05/03/2026	17	8501	75 136,34	19	13501	121 718,81
06/03/2026	21	12251	105 158,79	5	2251	19 478,80
09/03/2026	12	4001	34 237,08	25	21501	186 434,53
10/03/2026	16	10081	94 559,88	27	15081	143 252,91
11/03/2026	28	20201	184 760,16	12	6201	57 500,38
12/03/2026	37	17761	157 053,60	7	5261	47 500,67
13/03/2026	29	13501	115 709,92	13	15001	130 096,17
16/03/2026	12	6751	57 260,90	12	15751	135 593,43
17/03/2026	16	10001	87 693,77	19	13001	114 658,81
18/03/2026	14	11751	103 861,33	28	11001	98 820,77
19/03/2026	9	5751	50 347,53	33	27001	242 970,12
20/03/2026	35	24001	212 785,43	6	5501	50 535,38
23/03/2026	20	9251	79 950,66	20	24251	213 809,91
24/03/2026	40	30001	259 904,06	8	5001	45 054,06
25/03/2026	13	7001	59 283,63	8	5001	42 938,64
26/03/2026	36	16212	136 949,57	19	11487	97 593,67
27/03/2026	35	20076	167 456,33	33	20076	167 871,30
30/03/2026	42	12419	102 356,65	16	13321	110 390,59
31/03/2026	12	10128	84 572,34	22	15951	134 857,09
01/04/2026	12	6751	58 381,16	27	11501	100 017,41
02/04/2026	37	15251	129 017,36	11	17251	147 546,08
07/04/2026	142	81006	638 469,04	1	1	8,58
08/04/2026	43	22914	180 072,65	38	25169	201 030,09
09/04/2026	14	14001	110 385,42	20	42001	332 987,71
10/04/2026	1	1	8,02	64	59251	498 113,08
13/04/2026	19	7501	64 912,00	17	8251	73 140,99

PRESS RELEASE

14/04/2026	20	9826	90 235,40	20	27826	255 113,78
15/04/2026	23	13101	123 378,41	32	10601	100 433,87
16/04/2026	27	13751	126 516,35	5	2251	21 099,34
17/04/2026	27	10251	92 889,03	18	11251	102 460,04
20/04/2026	21	11001	99 908,99	16	8001	74 583,96
21/04/2026	31	14251	128 304,18	9	4251	39 049,13
22/04/2026	18	6752	59 455,34	6	752	6 655,46
23/04/2026	74	32250	271 523,07	11	4500	40 177,44
24/04/2026	20	10501	86 286,61	11	6751	56 363,22
27/04/2026	20	7900	64 510,14	12	5064	41 394,81
28/04/2026	47	20152	162 935,17	44	19001	153 894,61
29/04/2026	33	18251	144 993,06	24	10266	81 569,63
30/04/2026	29	16031	128 173,30	39	24235	194 083,57
04/05/2026	17	6230	50 669,09	25	5698	46 934,20
05/05/2026	21	5237	42 558,22	8	4036	33 177,57
06/05/2026	7	2500	20 730,05	14	5751	47 876,27
07/05/2026	16	6799	57 531,64	26	10001	84 805,98
08/05/2026	24	8633	71 211,20	19	10181	85 633,41
11/05/2026	18	4501	38 843,49	20	15462	136 373,14
12/05/2026	28	11412	99 934,20	22	11252	99 490,18
13/05/2026	9	5734	50 144,00	14	7985	70 905,36
14/05/2026	23	9551	85 059,87	23	11256	100 488,62
15/05/2026	37	16326	143 161,71	33	11448	100 732,10
18/05/2026	27	7539	63 792,61	12	6500	55 574,87
19/05/2026	12	6000	50 392,50	15	7661	64 878,40
20/05/2026	11	4501	37 958,51	17	7000	59 512,53
21/05/2026	31	9751	83 008,61	21	8751	74 882,48
22/05/2026	39	14501	124 332,59	1	1	8,74
25/05/2026	13	8751	75 443,60	8	4501	39 166,08
26/05/2026	26	13971	120 203,27	11	6971	60 499,43
27/05/2026	27	12721	107 364,10	24	12441	105 894,56
28/05/2026	20	8251	70 208,58	21	13531	115 811,83
29/05/2026	22	10210	89 995,94	16	7960	70 858,01
01/06/2026	16	10751	92 705,55	8	2251	20 078,83
02/06/2026	19	7730	66 376,74	16	5230	45 366,90
03/06/2026	22	10001	84 786,08	31	15002	127 952,06
04/06/2026	1	1	8,55	45	30000	268 256,40
05/06/2026	56	27966	255 864,29	30	13966	131 723,26
08/06/2026	30	15272	130 761,77	25	15272	131 671,06
09/06/2026	46	28501	243 832,90	13	6751	58 428,49

PRESS RELEASE

10/06/2026	31	15250	127 543,22	19	12114	101 593,21
11/06/2026	22	9079	77 802,94	31	18965	164 550,58
12/06/2026	24	12251	110 481,48	42	22001	203 289,02
15/06/2026	20	9001	85 321,92	52	24001	229 736,85
16/06/2026	31	20251	194 852,29	16	7553	75 032,79
17/06/2026	14	9053	84 701,14	20	12251	119 468,08
18/06/2026	4	1751	17 422,45	58	17501	182 626,09
19/06/2026	30	17251	175 765,44	38	26001	275 305,35
22/06/2026	31	13152	141 067,43	33	15402	167 344,27
23/06/2026	24	7751	81 719,10	57	24072	260 350,48
24/06/2026	50	19501	208 246,11	13	4930	54 895,99
25/06/2026	76	33251	320 218,44	3	3501	33 865,28
26/06/2026	21	8001	73 952,60	21	14501	142 513,22
29/06/2026	10	4751	49 870,15	76	18251	192 544,76
30/06/2026	41	19255	204 264,55	39	19255	205 728,89